ArihantCapital

Nova Agritech Limited

Neutral

Rating: Neutral

Issue Offer

Fresh Issue up to 27,317,073 shares and Offer for sale up to 7,758,620 equity shares

| Issue Summary | |
|--------------------------------|---------------|
| Price Band (INR) | 39-41 |
| Face Value (INR) | 2 |
| Implied Market Cap (INR Mn) | 3,793 |
| Market Lot | 365 |
| Issue Opens on | Jan, 22, 2024 |
| Issue Close on | Jan, 24, 2024 |
| No. of share pre-issue | 65,202,740 |
| No. of share post issue | 92,519,813 |
| Listing | NSE / BSE |
| Issue Break-up (%) | |

| Issue Break-up (%) | |
|--------------------|-----|
| QIB Portion | ≥50 |
| NII (HNI) Portion | ≤15 |
| Retail Portion | ≤35 |
| | |

Book Running Lead Managers Keynote Financial Services Ltd Bajaj Capital Limited

Registrar Bigshare Services Pvt Ltd

| Shareholding Pattern | | | |
|----------------------|-----------|------------|--|
| | Pre-Issue | Post-Issue | |
| Promoters | 84.27% | 59.39% | |
| Public & Others | 15.73% | 40.61% | |

Objects of the issue

Investment in subsidiary Nova Agri Sciences Private Limited (NASPL) for new formulation plant.

- Funding Capital Expenditure by our Company, towards expansion of our existing formulation plant
- Funding of working capital requirement of our Company
- Investment in subsidiary, Nova Agri Sciences Private Limited for funding working capital requirements

Abhishek Jain

abhishek.jain@arihantcapital.com 022-422548871

Business Overview

Nova Agritech Ltd. (NATL) incorporated in 2007 at Hyderabad, Andhra Pradesh is a prominent agri-input manufacturer with a focus on soil health management, crop nutrition, and crop protection through tech-driven farmercentric solutions. The company's diverse product range spans soil health management, crop nutrition, bio stimulants, bio pesticides, Integrated Pest Management, new technologies and crop protection. Notably, crop protection products are manufactured by its subsidiary, Nova Agri Sciences Private Ltd (NASPL). As of November 30, 2023, NOVA has garnered a total of 720 product registrations across various categories. The distribution network spans 16 states, encompassing around 11,722 dealers, with approximately 6,769 active dealers in the current financial year. Additionally, the company has expanded its reach internationally with distributors in Nepal and strategic agreements in Bangladesh, Sri Lanka, and Vietnam, pending regulatory approvals for business initiation in these regions.

Investment Rationale

Augmenting Competencies and Expanding Manufacturing Capacities

NATL intends to invest in NASPL for setting-up a new formulation plant and funding the capital expenditure in NATL. To enhance the product range and production capacity, the company plans to increase the capacity of Suspension Concentrate (SC) formulations and can add new formulation types like Capsule Suspension (CS), Suspo Emulsion (SE), Mixed formulation of CS & SC (ZC), Water Dispersible Granules (WDG) and Granules. NATL plans to expand its product portfolio by offering new generation products created and formulated based on patented formulations, thus creating a wider catalogue of enhanced modern products ready to be offered to the farmers to cater to their farming needs at various levels.

Strategic Expansion through Technicals Distribution

NOVA AGRITECH is set to play a pivotal role in fostering the growth of the Indian agriculture sector by importing and distributing Technicals. In a strategic move, the company has inked Registration and Distribution Agreements with a Taiwanese entity for the import and distribution of Butachlor 85% Tech and with a Chinese entity for Emamectin Benzoate Technical 95%. These agreements, effective for a substantial 5-year period, signify NOVA's commitment to bringing essential agricultural technologies to India, positioning itself as a key player in the sector's development..

Innovative Growth Initiatives and R&D Focus

In addition to the existing 720 product registrations covering diverse categories, NOVA AGRITECH is poised for further expansion with 14 new product registrations under NASPL and 22 under NATL. The company is strategically positioning itself for continued innovation and excellence by seeking Department of Scientific and Industrial Research (DSIR) certification for its in-house R&D projects.

Valuation and View:

NOVA AGRITECH is promising with its diverse agri-input portfolio, strategic expansion through technical imports, and a focus on innovation and research. The company's international presence and investments in manufacturing capacities signal a forward-looking approach. At the upper band of INR 41, the issue is valued at a P/E of 18.3x based on H1FY24 EPS of INR 1.66 (post issue) which is rich valuations compared to listed Peers. Hence, we have a Neutral rating as we remain cautious on agro chemicals sector which is facing headwinds.

Arihant Capital Markets Limited Research Analyst SEBI Registration No: INH000002764 1011, Solitaire Corporate Park, Bldg No.10, 1st Floor, Andheri Ghatkopar Link Rd, Chakala, Andheri (E), Mumbai 400093

Financial Statements

Income statement summary

| Income statement summary | | | |
|-------------------------------|---------|---------|---------|
| Y/E 31 Mar (INR mn) | FY21 | FY22 | FY23 |
| Revenue | 1,606 | 1,856 | 2,106 |
| Operating expenses | 990 | 1,135 | 1,213 |
| Gross Profit | 616 | 721 | 892 |
| Gross Margin (%) | 38.3% | 38.9% | 42.4% |
| Employee Cost | 221 | 265 | 273 |
| Other Expenses | 216 | 178 | 232 |
| EBITDA | 179 | 278 | 387 |
| EBITDA Margin (%) | 11.1% | 15.0% | 18.4% |
| Depreciation | -21 | -22 | -24 |
| Interest expense | -73 | -72 | -86 |
| Other income | 3 | 0 | 4 |
| Exceptional item | 0 | 0 | 0 |
| Profit before tax | 87 | 184 | 282 |
| Taxes | 24 | 48 | 77 |
| РАТ | 63 | 137 | 205 |
| PAT Margin (%) | 3.9% | 7.4% | 9.7% |
| EPS (INR) | 1.00 | 2.18 | 3.27 |
| Balance Sheet Summary | | | |
| Y/E 31 Mar (INR Mn) | FY21 | FY22 | FY23 |
| Equity Capital | 125.41 | 125.41 | 125.41 |
| Reserves | 168.89 | 306.51 | 513.39 |
| Net worth | 294.30 | 431.91 | 638.80 |
| Minority Interest | 0.00 | 0.00 | 0.00 |
| Provisions | 7.17 | 9.30 | 8.92 |
| Long term borrowings | 183.52 | 236.38 | 163.57 |
| Other non-current liabilities | 40.09 | 7.19 | 7.11 |
| Total Liabilities | 1474.39 | 1602.98 | 1807.83 |
| Fixed assets | 160.07 | 168.24 | 155.76 |
| Capital Work In Progress | 0.00 | 0.50 | 6.30 |
| Other Intangible assets | 0.42 | 0.31 | 1.18 |
| Goodwill | 11.62 | 11.62 | 11.62 |
| Investments | 0.00 | 0.00 | 0.00 |
| Other non-current assets | 35.69 | 41.75 | 45.73 |
| Non Current Assets | 207.80 | 222.42 | 220.59 |
| Inventories | 354.23 | 367.96 | 417.21 |
| Sundry debtors | 849.76 | 929.86 | 1056.76 |
| Short Term borrowings | 327.50 | 406.28 | 545.98 |
| Other current assets | 50.37 | 59.02 | 76.61 |
| Sundry creditors | 463.29 | 324.81 | 272.76 |
| Other financial liabilities | 65.57 | 70.63 | 59.53 |
| Other current liabilities & | | | |
| Prov | 92.96 | 116.48 | 111.17 |
| Cash | 3.16 | 16.42 | 33.52 |
| Other Financial Assets | 9.08 | 7.30 | 3.14 |
| Total Assets | 1474.39 | 1602.98 | 1807.83 |

| Cashflow summary | | | |
|-------------------------|---------|--------------|---------|
| Y/E 31 Mar (INR Mn) | FY21 | FY22 | FY23 |
| Profit before tax | 86.71 | 184.45 | 281.64 |
| Depreciation | 21.45 | 22.25 | 23.61 |
| Interest | 73.33 | 71.51 | 43.45 |
| Change in Working | -125.20 | -226.31 | -278.46 |
| Capital Tax paid | 23.71 | 47.55 | 76.74 |
| Operating cashflow | 51.81 | 24.82 | 54.49 |
| Proceeds from Purchase | 51.01 | 24.02 | 54.45 |
| and sale of PPE | -30.73 | -40.56 | -22.68 |
| Investing Cashflow | -31.23 | -38.78 | -18.57 |
| Proceeds from | 36.21 | 93.95 | 70.17 |
| borrowings | | | _ |
| Interest Paid | -73.33 | -71.51 | -85.72 |
| Financing Cashflow | -18.30 | 27.23 | -18.83 |
| Net cashflow | 2.28 | 13.27 | 17.10 |
| Opening Cash | 0.87 | 3.16 | 16.42 |
| Closing Cash Flow | 3.16 | 16.42 | 33.52 |
| Ratio Analysis | FV24 | EV22 | EV/22 |
| Y/E 31 Mar (INR Mn) | FY21 | FY22 | FY23 |
| Growth matrix (%) | | 45 50/ | 12.40/ |
| Revenue growth | | 15.5% | 13.4% |
| PAT growth | | 117.3% | 49.7% |
| Profitability ratio (%) | | | |
| Net Profit Margin | 3.92% | | 9.73% |
| ROCE | 29.9% | | 44.4% |
| ROE | 21.4% | | 32.1% |
| ROA | 4.3% | 8.5% | 11.3% |
| Per share ratio (INR) | | | |
| EPS | 1 | 2.18 | 3.27 |
| Cash EPS | 0.83 | | 0.87 |
| Book value per share | 4.69 | 6.89 | 10.19 |
| Valuation ratio (x) | | | |
| P/E | 41.00 | | 12.54 |
| P/CEPS | 49.62 | 103.59 | 47.18 |
| P/B | 8.74 | 5.95 | 4.02 |
| EV/EBITDA | 18.18 | 11.68 | 8.39 |
| Payout (%) | | | |
| Tax Payout | 27.3% | 25.8% | 27.2% |
| Liquidity ratio | | | |
| Debtor days | 193.08 | 182.87 | 183.19 |
| Inventory days | 130.54 | | 125.50 |
| Creditor days | 123.96 | | 59.57 |
| WC days | 199.66 | 225.37 | 249.12 |

Story in Charts

Exhibit 1. Revenue from Operations has grown at a CAGR of 16.1% from FY21 to FY23



Exhibit 3: The PAT has shown consistent increase from last 3 financial years





Exhibit 5: Consistent Improvement in ROCE, ROE, and ROA Trends Over Three Financial Years



Source: RHP, Company Reports, Arihant Capital Research

Exhibit 2: Over the past three years, the company's EBITDA margins have consistently increased





Exhibit 4: Working capital has reduced in terms of sales.



Exhibit 6: Steady Increase in EPS over last 3 Financial Years



Arihant Research Desk

Email: instresearch@arihantcapital.com

Tel. : 022-42254800

| Head Office | Registered Office |
|--|-------------------------|
| #1011, Solitaire Corporate Park | |
| Building No. 10, 1 st Floor | Arihant House |
| Andheri Ghatkopar Link Road | E-5 Ratlam Kothi |
| Chakala, Andheri (E) | Indore - 452003, (M.P.) |
| Mumbai – 400093 | Tel: (91-731) 3016100 |
| Tel: (91-22) 42254800 | Fax: (91-731) 3016199 |
| Fax: (91-22) 42254880 | |
| | |
| Stock Rating Scale | Absolute Return |
| BUY | >20% |
| ACCUMULATE | 12% to 20% |
| HOLD | 5% to 12% |
| NEUTRAL | -5% to 5% |
| REDUCE | -5% to -12% |

SELL

| Research Analyst Registration No. | Contact | Website | Email Id |
|--------------------------------------|-------------------------|------------------------|-------------------------------------|
| INH000002764 | SMS: 'Arihant' to 56677 | www.arihantcapital.com | instresearch@arihantcapital. com |

<-12%

Disclaimer: This document has been prepared by Arihant Capital Markets Ltd. This document does not constitute an offer or solicitation for the purchase and sale of any financial instrument by Arihant. This document has been prepared and issued on the basis of publicly available information, internally developed data and other sources believed to be reliable. Whilst meticulous care has been taken to ensure that the facts stated are accurate and opinions given are fair and reasonable, neither the analyst nor any employee of our company is in any way is responsible for its contents and nor is its accuracy or completeness guaranteed. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Arihant may trade in investments, which are the subject of this document or in related investments and may have acted upon or used the information contained in this document or the research or the analysis on which it is based, before its publication. This is just a suggestion and Arihant will not be responsible for any profit or loss arising out of the decision taken by the reader of this document. Affiliates of Arihant may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. No matter contained in this document may be reproduced or copied without the consent of the firm.

Arihant Capital Markets Ltd. 1011, Solitaire Corporate park, Building No. 10, 1st Floor, Andheri Ghatkopar Link Road, Chakala, Andheri (E) Tel. 022-42254800Fax. 022-42254880